Thursday, August 13, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
OLC Is Moving Forward. Unicycive reported a 2Q26 loss of $1.7 million, or $(0.06) per share. The Operating Loss of $10.1 million was offset by $8.0 million in Change In Fair Value Of Warrant Liabilities, leading to a Net Loss To Common Shareholders of $1.7 million. Importantly, the FDA has given written notice of facility inspection to one of the OLC third-party manufacturers. Assuming the inspection results are positive, Unicycive will be able to resubmit its NDA for OLC. Cash and equivalents on June 30, 2026, were $61.4 million.
The Third-Party Inspection Could Complete The Missing Part Of The NDA. In June 2026, Unicycive received a CRL (Complete Response Letter) to its NDA for OLC. The stated reason was that the required FDA inspection of one of its third-party manufacturing vendors had not been performed. The notification of an inspection is good news that could allow the NDA to be resubmitted.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.